The epitope arrangement on flavivirus particles contributes to Mab C10's extraordinary neutralization breadth across Zika and dengue viruses
- PMID: 34852239
- PMCID: PMC8724787
- DOI: 10.1016/j.cell.2021.11.010
The epitope arrangement on flavivirus particles contributes to Mab C10's extraordinary neutralization breadth across Zika and dengue viruses
Abstract
The human monoclonal antibody C10 exhibits extraordinary cross-reactivity, potently neutralizing Zika virus (ZIKV) and the four serotypes of dengue virus (DENV1-DENV4). Here we describe a comparative structure-function analysis of C10 bound to the envelope (E) protein dimers of the five viruses it neutralizes. We demonstrate that the C10 Fab has high affinity for ZIKV and DENV1 but not for DENV2, DENV3, and DENV4. We further show that the C10 interaction with the latter viruses requires an E protein conformational landscape that limits binding to only one of the three independent epitopes per virion. This limited affinity is nevertheless counterbalanced by the particle's icosahedral organization, which allows two different dimers to be reached by both Fab arms of a C10 immunoglobulin. The epitopes' geometric distribution thus confers C10 its exceptional neutralization breadth. Our results highlight the importance not only of paratope/epitope complementarity but also the topological distribution for epitope-focused vaccine design.
Keywords: Dengue virus; Flaviviruses; X-ray crystallography; Zika virus; broadly neutralizing antibodies; cryo-EM; vaccine design.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests F.A.R. is a board member and shareholder of EureKARE and MELETIUS Therapeutics. G.R.S. is member of the GSK Vaccines Scientific Advisory Board and a founding shareholder of RQ Biotechnology. G.R.S., F.A.R., P.G.-C., M.-C.V, A.R., S.D., and J.M. are authors in a patent concerning EDE mAbs, including C8 and C10:US20180037611A1 (2018): Anti-dengue vaccines and antibodies. G.R.S., F.A.R., M.-C.V., A.R., and J.M. are authors of patent CA3066488A1 (2017): Neutralising antibody against dengue for use in a method of prevention and/or treatment.
Figures















Comment in
-
How a broadly neutralizing antibody grapples with antigenic and conformational diversity in dengue virus.Cell. 2021 Dec 9;184(25):6015-6016. doi: 10.1016/j.cell.2021.11.020. Epub 2021 Dec 1. Cell. 2021. PMID: 34856127
Similar articles
-
Human antibody C10 neutralizes by diminishing Zika but enhancing dengue virus dynamics.Cell. 2021 Dec 9;184(25):6067-6080.e13. doi: 10.1016/j.cell.2021.11.009. Epub 2021 Nov 30. Cell. 2021. PMID: 34852238
-
Mechanism of differential Zika and dengue virus neutralization by a public antibody lineage targeting the DIII lateral ridge.J Exp Med. 2020 Feb 3;217(2):e20191792. doi: 10.1084/jem.20191792. J Exp Med. 2020. PMID: 31757867 Free PMC article.
-
Structural Basis of Zika Virus Specific Neutralization in Subsequent Flavivirus Infections.Viruses. 2020 Nov 24;12(12):1346. doi: 10.3390/v12121346. Viruses. 2020. PMID: 33255202 Free PMC article.
-
Cross-reactive dengue virus-derived monoclonal antibodies to Zika virus envelope protein: Panacea or Pandora's box?BMC Infect Dis. 2018 Dec 10;18(1):641. doi: 10.1186/s12879-018-3572-0. BMC Infect Dis. 2018. PMID: 30526531 Free PMC article. Review.
-
Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection.Front Immunol. 2018 Apr 23;9:597. doi: 10.3389/fimmu.2018.00597. eCollection 2018. Front Immunol. 2018. PMID: 29740424 Free PMC article. Review.
Cited by
-
Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development.Lancet Infect Dis. 2025 Jul;25(7):e402-e415. doi: 10.1016/S1473-3099(24)00750-3. Epub 2025 Feb 27. Lancet Infect Dis. 2025. PMID: 40024262 Free PMC article. Review.
-
Antibodies from dengue patients with prior exposure to Japanese encephalitis virus are broadly neutralizing against Zika virus.Commun Biol. 2024 Jan 24;7(1):15. doi: 10.1038/s42003-023-05661-w. Commun Biol. 2024. PMID: 38267569 Free PMC article.
-
Evolution of a functionally intact but antigenically distinct DENV fusion loop.Elife. 2023 Sep 19;12:RP87555. doi: 10.7554/eLife.87555. Elife. 2023. PMID: 37725085 Free PMC article.
-
In Silico Evaluation of Potential Hit Molecules Against Multiple Serotypes of Dengue Virus Envelope Glycoprotein.Molecules. 2025 Mar 12;30(6):1268. doi: 10.3390/molecules30061268. Molecules. 2025. PMID: 40142044 Free PMC article.
-
Identification and analysis of B cell epitopes of hemagglutinin of H1N1 influenza virus.Arch Microbiol. 2022 Sep 2;204(9):594. doi: 10.1007/s00203-022-03133-z. Arch Microbiol. 2022. PMID: 36053375 Free PMC article.
References
-
- Barba-Spaeth G., Dejnirattisai W., Rouvinski A., Vaney M.C., Medits I., Sharma A., Simon-Lorière E., Sakuntabhai A., Cao-Lormeau V.M., Haouz A., et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature. 2016;536:48–53. - PubMed
-
- Blanc E., Roversi P., Vonrhein C., Flensburg C., Lea S.M., Bricogne G. Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. Acta Crystallogr. D Biol. Crystallogr. 2004;60:2210–2221. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical